Zaja F, Di Loreto C, Amoroso V, Salmaso F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L, Mariuzzi L, Beltrami C A, Baccarani M
Department of Medical and Morphological Research, Udine University Hospital, P.le S. Maria della Misericordia, Italy.
Leuk Lymphoma. 1998 Feb;28(5-6):567-72. doi: 10.3109/10428199809058365.
Bcl-2 overexpression has been shown to be associated with several malignancies, including B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphomas (NHL), mainly low-grade and follicular in type. It has as yet not been described in hairy cell leukemia (HCL). In 30 patients with CLL and 14 with HCL who were consecutively selected for treatment with purine analogues (Fludarabine in CLL and 2-chloro-deoxy-adenosine in HCL), we evaluated bcl-2 oncoprotein expression in leukemic cells on marrow sections that were taken before treatment and stained immunohistochemically with a monoclonal antibody (Dakopatts 124 clone), by the avidin-biotin-peroxidase method. All samples were found to be bcl-2 positive, with a staining intensity that was moderate to strong in CLL and weak to moderate in HCL. 83% of CLL and 100% of HCL patients were responsive to purine analogues. These findings show that bcl-2 is overexpressed in almost all cases CLL and HCL and that bcl-2 overexpression does not predict a poor response to purine analogues, which are believed to induce apoptosis.
Bcl-2过表达已被证明与多种恶性肿瘤相关，包括B细胞慢性淋巴细胞白血病（CLL）和非霍奇金淋巴瘤（NHL），主要为低级别和滤泡型。毛细胞白血病（HCL）中尚未有相关描述。在30例接受嘌呤类似物治疗（CLL用氟达拉滨，HCL用2-氯脱氧腺苷）的CLL患者和14例HCL患者中，我们评估了治疗前骨髓切片中白血病细胞的bcl-2癌蛋白表达，采用抗生物素蛋白-生物素-过氧化物酶法，用单克隆抗体（Dakopatts 124克隆）进行免疫组织化学染色。所有样本均为bcl-2阳性，CLL的染色强度为中度至强，HCL为弱至中度。83%的CLL患者和100%的HCL患者对嘌呤类似物有反应。这些发现表明，几乎所有CLL和HCL病例中bcl-2均过表达，且bcl-2过表达并不能预测对被认为可诱导凋亡的嘌呤类似物反应不佳。
